Cepheid announced it has received clearance from the Food and Drug Administration (FDA) to market Xpert Norovirus, an in vitro diagnostic test for identification and differentiation of Noroviruses ...
Managing One of the Largest Enterovirus Testing Populations, Children's Medical Center Dallas Among Leading Institutions to Quickly Adopt Cepheid's SUNNYVALE, Calif ...
SUNNYVALE, Calif., May 29, 2019 /PRNewswire/ -- Cepheid announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for testing throat and rectal specimens with its ...
Evaluation of the Xpert MTB/RIF Test for the Diagnosis of Childhood Pulmonary Tuberculosis in Uganda
In the policy statement on the Xpert MTB/RIF test in 2011, the WHO recommended the use of the test as an initial diagnostic tool among children with suspected HIV associated TB or MDR TB based on ...
Co announces it received clearance from the FDA to market its Xpert EV test, which runs on the GeneXpert System, for the presumptive qualitative detection of enterovirus RNA in cerebrospinal fluid as ...
SUNNYVALE, Calif., Oct. 28, 2025 /PRNewswire/ -- Cepheid today announced that its Xpert® MTB/XDR test has been awarded prequalification status by the World Health Organization (WHO), marking a new ...
In an HIV-positive population, the Xpert MTB/RIF Ultra assay detected tuberculous meningitis with higher sensitivity than the older Xpert assay and a mycobacterial growth indicator tube culture, ...
Co announces it received clearance from the FDA to market its Xpert M.R.S.A test, which runs on the GeneXpert System, for the rapid detection of Methicillin-resistant Staphylococcus aureus. "Currently ...
Tuberculosis (TB) causes more deaths globally than any other infectious disease and is a top 10 cause of death worldwide. Globally in 2017, of the estimated 10 million people with TB, 3.6 million were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results